Alligator Bioscience AB
STO:ATORX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Alligator Bioscience AB
Other Current Liabilities
Alligator Bioscience AB
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Alligator Bioscience AB
STO:ATORX
|
Other Current Liabilities
kr36.1m
|
CAGR 3-Years
128%
|
CAGR 5-Years
81%
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Other Current Liabilities
kr199.1m
|
CAGR 3-Years
66%
|
CAGR 5-Years
46%
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Other Current Liabilities
kr140.4m
|
CAGR 3-Years
32%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Other Current Liabilities
kr146m
|
CAGR 3-Years
23%
|
CAGR 5-Years
34%
|
CAGR 10-Years
14%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Other Current Liabilities
kr2.6B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
16%
|
|
|
BioArctic AB
STO:BIOA B
|
Other Current Liabilities
kr505.1m
|
CAGR 3-Years
132%
|
CAGR 5-Years
42%
|
CAGR 10-Years
N/A
|
|
Alligator Bioscience AB
Glance View
Alligator Bioscience AB is a biotech company, which engages in the development of innovative antibody-based medicines for immunotherapy of cancer. The company is headquartered in Lund, Skane and currently employs 46 full-time employees. The company went IPO on 2016-11-23. The firm specializes in the development of tumor-targeted immunotherapies, in particular agonist mono- and bispecific antibodies, and is active in the early stages of drug development, from concept to phase II clinical trials. Alligator’s pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its technology platform, Neo-X-Prime, with MacroGenics Inc. and drug candidates based on the RUBY bispecific platform with Orion Corporation. Its licensed programs include AC101, in phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. The firm operates domestically.
See Also
What is Alligator Bioscience AB's Other Current Liabilities?
Other Current Liabilities
36.1m
SEK
Based on the financial report for Dec 31, 2025, Alligator Bioscience AB's Other Current Liabilities amounts to 36.1m SEK.
What is Alligator Bioscience AB's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
81%
Over the last year, the Other Current Liabilities growth was -74%. The average annual Other Current Liabilities growth rates for Alligator Bioscience AB have been 128% over the past three years , 81% over the past five years .
